Daviskas Evangelia, Anderson Sandra D, Gomes Kerry, Briffa Peter, Cochrane Belinda, Chan H-Kim, Young Iven H, Rubin Bruce K
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Respirology. 2005 Jan;10(1):46-56. doi: 10.1111/j.1440-1843.2005.00659.x.
Inhaled mannitol increases mucus clearance in patients with bronchiectasis by an unclear mechanism. The effect of mannitol on lung function, health status and sputum properties was investigated.
Nine patients with bronchiectasis inhaled 400 mg of mannitol once daily for 12 days. Health status was assessed using the St George's Respiratory Questionnaire (SGRQ). Sputum was analysed for viscosity, elasticity, spinnability, surface tension, contact angle, solids, mucociliary transportability (MCTR) on a frog palate, and cough transportability (CTR) on a simulated cough machine.
Lung function was unchanged with treatment (baseline FEV1 82.0 +/- 16.2%) apart from an improvement in FEF from 85.4 +/- 13% (baseline) to 90.7 +/- 14.4% (P < 0.05; 12th treatment; visit 7). The total SGRQ score (mean +/- SD) of 49.3 +/- 13.8 at baseline, decreased by 12.4 +/- 10.2 (P < 0.01; visit 7) and 10.1 +/- 9.4 units (P < 0.02) 6-10 days after treatment cessation. The baseline subscores for symptoms (72.9 +/- 11.8), activity (44.7 +/- 20.9) and impact (44.4 +/- 14.3) were reduced by 0.8 +/- 9.1 (P > 0.7), 8.4 +/- 16.0 (P > 0.1) and 19.2 +/- 13.7 (P < 0.005) units, respectively (visit 7). Mannitol reduced the baseline (mean +/- SE) surface tension from 94.5 +/- 1.4 to 84.7 +/- 2.1 mN/m (P < 0.0001), contact angle from 51.1 +/- 2.8 to 33.2 +/- 2.4 degrees (P < 0.0001), spinnability from 11.6 +/- 0.4 to 10.0 +/- 0.2 mm (P < 0.005), and solids from 5.7 +/- 0.4 to 4.3 +/- 0.7% (P < 0.02), acutely (visit 7). Viscosity, elasticity and MCTR did not change significantly, while CTR was increased from 25.8 +/- 1.0 to 34.1 +/- 2.7 mm (P < 0.003).
Mannitol significantly improved the health status over 12 days and this improvement was maintained for 6-10 days after cessation of treatment. In addition, mannitol reduced the tenacity, increased the hydration of mucus acutely and improved cough clearability in patients with bronchiectasis.
吸入甘露醇可增加支气管扩张症患者的黏液清除率,但其机制尚不清楚。本研究旨在探讨甘露醇对肺功能、健康状况和痰液性质的影响。
9例支气管扩张症患者每天吸入400mg甘露醇,共12天。采用圣乔治呼吸问卷(SGRQ)评估健康状况。分析痰液的黏度、弹性、可纺性、表面张力、接触角、固体成分、在蛙腭上的黏液纤毛运输能力(MCTR)以及在模拟咳嗽机上的咳嗽运输能力(CTR)。
除用力呼气流量(FEF)从基线时的85.4±13%改善至90.7±14.4%(P<0.05;第12次治疗;第7次访视)外,治疗期间肺功能无变化(基线第1秒用力呼气容积[FEV1]为82.0±16.2%)。基线时SGRQ总评分(均值±标准差)为49.3±13.8,在停止治疗6 - 10天后降低了12.4±10.2(P<0.01;第7次访视)和10.1±9.4分(P<0.02)。症状(72.9±11.8)、活动(44.7±20.9)和影响(44.4±14.3)的基线子评分分别降低了0.8±9.1(P>0.7)、8.4±16.0(P>0.1)和19.2±13.7分(P<0.005)(第7次访视)。甘露醇可使基线时(均值±标准误)的表面张力从94.5±1.4降至84.7±2.1mN/m(P<0.0001),接触角从51.1±2.8降至33.2±2.4度(P<0.0001),可纺性从11.6±0.4降至10.0±0.2mm(P<0.005),固体成分从5.7±0.4降至4.3±0.7%(P<0.